Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson’s disease-Reference-Cited by-同舟云学术

Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson’s disease

Published:2020-02 Issue:2 Volume:25 Page:392-405
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Chawla Sunita,Kalyane Dnyaneshwar,Tambe Vishakha,Deb Pran Kishore,Kalia Kiran,Tekade Rakesh K.

Funder

Science and Engineering Research Board (Statutory Body Established through an Act of Parliament: SERB Act 2008), Department of Science and Technology (DST), Government of India

DST-SERB

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference85 articles.

1. Epidemiology of Parkinson’s disease;De Lau;Lancet Neurol.,2006

2. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity;van Den Eeden;Am. J. Epidemiol.,2003

3. Neurological disorders: public health challenges;WHO,2006

4. Parkinson’s disease symptoms: the patient’s perspective;Politis;Movement Disorders,2010

5. Non-motor symptoms of Parkinson’s disease: diagnosis and management;Chaudhuri;Lancet Neurol.,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanocarrier Mediated Intranasal Drug Delivery Systems for the Management of Parkinsonism: A Review;Current Drug Delivery;2024-06

2. Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery;Biochemical Pharmacology;2022-01

3. Biomaterials and stem cells as drug/gene-delivery vehicles for Parkinson's treatment: an update;Regenerative Medicine;2021-12

4. Designing nanoformulation for the nose‐to‐brain delivery in Parkinson's disease: Advancements and barrier;WIREs Nanomedicine and Nanobiotechnology;2021-11-25

5. Recent advancements and future submissions of silica core-shell nanoparticles;International Journal of Pharmaceutics;2021-11